

# Jintian He

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5979205/publications.pdf>

Version: 2024-02-01

15  
papers

224  
citations

1040056

9  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

431  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer. <i>International Journal of Pharmaceutics</i> , 2011, 416, 69-76.	5.2	45
2	Stabilization and encapsulation of a staphylokinase variant (K35R) into poly(lactic-co-glycolic acid) microspheres. <i>International Journal of Pharmaceutics</i> , 2006, 309, 101-108.	5.2	34
3	Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 109, 24-34.	4.3	32
4	Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride. <i>International Journal of Pharmaceutics</i> , 2018, 553, 375-385.	5.2	22
5	Construction and Characterization of Novel Staphylokinase Variants with Antiplatelet Aggregation Activity and Reduced Immunogenicity. <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 336-342.	2.0	14
6	Stable thermosensitive in situ gel-forming systems based on the lyophilizate of chitosan/ $\beta$ -glycerophosphate salts. <i>International Journal of Pharmaceutics</i> , 2016, 511, 560-569.	5.2	14
7	Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method. <i>Journal of Microencapsulation</i> , 2011, 28, 763-770.	2.8	13
8	Formulation and evaluation of poly(lactic-co-glycolic acid) microspheres loaded with an altered collagen type II peptide for the treatment of rheumatoid arthritis. <i>Journal of Microencapsulation</i> , 2015, 32, 608-617.	2.8	13
9	Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase. <i>Acta Biochimica Et Biophysica Sinica</i> , 2014, 46, 782-791.	2.0	9
10	Stabilization and immune response of HBsAg encapsulated within poly(lactic-co-glycolic acid) microspheres using HSA as a stabilizer. <i>International Journal of Pharmaceutics</i> , 2015, 496, 332-341.	5.2	8
11	Refolding of a Staphylokinase Variant Y1-Sak by Reverse Dilution. <i>Applied Biochemistry and Biotechnology</i> , 2008, 151, 29-41.	2.9	5
12	Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini. <i>Biotechnology and Applied Biochemistry</i> , 2008, 50, 17.	3.1	4
13	Simultaneous elimination of T- and B-cell epitope by structure-based mutagenesis of single Glu80 residue within recombinant staphylokinase. <i>Acta Biochimica Et Biophysica Sinica</i> , 2010, 42, 209-215.	2.0	4
14	Co-delivery of polyinosinic:polycytidylic acid and flagellin by poly(lactic-co-glycolic acid) MPs synergistically enhances immune response elicited by intranasally delivered hepatitis B surface antigen. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6617-6632.	6.7	4
15	Purification and characterization of a staphylokinase variant, K35R. <i>Biotechnology and Applied Biochemistry</i> , 2006, 45, 43.	3.1	3